News & Insights

Cases & Deals

September 27, 2016

King & Spalding Advises EndoChoice in $210 Million Sale to Boston Scientific

ATLANTA, Sept. 27, 2016 — King & Spalding advised EndoChoice Holdings, Inc. (NYSE: GI) in connection with a definitive merger agreement under which EndoChoice will be acquired by Boston Scientific Corporation (NYSE: BSX). Upon completion of the transaction, EndoChoice will become part of the Boston Scientific endoscopy business.

Under the terms of the agreement, Boston Scientific will launch a tender offer for all EndoChoice outstanding shares at a cash price of $8.00 per share. Following the tender offer, if successful, all remaining shares of EndoChoice will receive in a merger transaction the same consideration paid to stockholders who participated in the tender offer. The total equity value of the transaction is approximately $210 million and the transaction is expected to close in the fourth quarter of 2016 subject to customary closing conditions.

The King & Spalding corporate team on this deal includes partners Keith Townsend, Rob Leclerc and Alana Griffin and associates John Anderson, Zack Davis and Brian Park. Additional assistance was provided by partners John Sweet (tax), Elaine Tseng (FDA), Rob Keenan (healthcare), Sam Choy (executive compensation and employee benefits), Becky Kaufman (intellectual property) and Michael Taylor (international trade); and counsel John Carroll (antitrust), Mark Kelly (executive compensation and employee benefits), Scott Mario (labor) and Laura Bennett (FCPA).

Ranked as one of the world’s leading advisors in M&A transactions worldwide, King & Spalding has been representing its clients—from Fortune 100 corporations to emerging growth companies—for decades in the most sophisticated transactions covering the full spectrum of mergers and acquisitions transactions.

About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 900 lawyers in 18 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at